Nectar Lifescience secures ANVISA (Brazil) cGMP

Capital Market

Last Updated : May 14 2015 | 8:01 PM IST

For Cephalosporin API's manufacturing facility

Nectar Lifescience has received ANVISA cGMP (current good manufacturing practices) approval for Brazil for its Cephalosporin API's manufacturing facility in Dera Bassi, Punjab.

Powered by Capital Market - Live News

More From This Section

Future Market Networks completes sale of investment in River Bank Project

AGC Networks approves grant of stock options

MPIL Corporation delists shares from Calcutta Stock Exchange

KNR Constructions secures NHAI order

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: May 14 2015 | 6:31 PM IST

Explore News

IND vs NZ LIVE SCORE Padma Awards 2026 Q3 Results Today Delhi AQI Today IMD Weather Forecast Today WEF 2026 Day 4 Shadowfax Technologies IPO WEF 2026 Day 5 Key Speakers Stock Market Holiday Personal Finance